SAVA Stock Risk & Deep Value Analysis

Cassava Sciences maintains theoretical 10x growth potential due to its focus on the vast Alzheimer's market with simufilam. However, this potential remains critically undermined by persistent, unresolved allegations of data manipulation, scientific misconduct, and ongoing regulatory investigations (FDA, NIH). These fundamental integrity issues continue to create profound trust deficits with leadership and the scientific community, severely compromising any realistic path to approval and sustainable commercialization. As of 2026-03-20, there have been no material positive developments to resolve these critical red flags. The company's financial runway is likely constrained by trial costs and difficulty in attracting new capital due to these controversies. The stock represents extreme speculative risk with a very low likelihood of achieving sustainable growth or market leadership due to these unresolved foundational integrity issues.